

## OncoMed Pharmaceuticals Inc

### CORTELLIS COMPANY DETAILED PIPELINE REPORT

A comprehensive coverage of the the company's drug pipeline portfolio including detailed product records.

Publication Date: 18-Feb-2014

#### THOMSON REUTERS

3 Times Square  
New York, New York 10036  
United States

Tel: +1 646 223 4000

[thomsonreuters.com](http://thomsonreuters.com)

[Return to Table of Contents](#)

## ABOUT CORTELLIS COMPANY DETAILED PIPELINE REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

*Cortellis* Company Detailed Pipeline reports are the second in a series of that track pharmaceutical and biotechnology companies worldwide. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from over 400 global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

**Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence***

### DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



## GLOSSARY

### Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

### Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

### Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

### Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

### Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

### Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

### Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 5

Company Profile..... 6

Product Portfolio Summary..... 7

Product Portfolio Drug Pipeline Detail..... 10

    Phase 2 Clinical..... 11

    Phase 1 Clinical..... 23

    Discovery..... 41

[Return to Table of Contents](#)

# OncoMed Pharmaceuticals Inc

## COMPANY OVERVIEW

Company Name	OncoMed Pharmaceuticals Inc
Parent Company Name	OncoMed Pharmaceuticals Inc
Website	<a href="http://www.oncomed.com/">http://www.oncomed.com/</a>
Country	US
Number of Drugs in Active Development	8
Number of Inactive Drugs	0
Number of Patents as Owner	35
Number of Patents as Third Party	1
Number of Deals	12
Key Indications	Cancer,Solid tumor,Pancreas tumor,Colorectal tumor,Ovary tumor,Breast tumor,Lung tumor,Hematological neoplasm,Non-small-cell lung cancer,Small-cell lung cancer
Key Target-based Actions	Delta-like protein ligand 4 inhibitor,VEGF receptor antagonist,Notch-1 receptor antagonist,Notch-2 receptor antagonist,Notch-3 receptor antagonist,Frizzled-7 receptor antagonist,Frizzled-8 receptor antagonist,Leucine rich repeat containing protein modulator,Notch receptor modulator,RSPO3 gene inhibitor
Key Technologies	Biological therapeutic,Parenteral formulation unspecified,Infusion,Intravenous formulation,Monoclonal antibody humanized,Immunoglobulin-G,Monoclonal antibody human,Antibody,Monoclonal antibody,Drug combination,Peptide,Protein fusion,Small molecule therapeutic

## COMPANY PROFILE

### SUMMARY

OncoMed, established in 2004 and headquartered in Mountain View, CA, is a biotechnology company that discovers and develops mAbs and small molecules targeting biological pathways to destroy cancer stem cells.

### LICENSING AGREEMENTS

In January 2010, OncoMed Pharmaceuticals and Fluidigm Corporation agreed to apply Fluidigm's microfluidic tools to the analysis of tumor cell heterogeneity. Financial details were undisclosed.

In June 2006, MorphoSys granted OncoMed Pharmaceuticals access to HuCAL GOLD antibody therapy use in cancer drug discovery programs. The agreement included an upfront payment and annual user fees. In June 2008, OncoMed exercised its option to extend its license agreement for MorphoSys' HuCAL GOLD antibody library and initiated development of two cancer stem cell therapeutic antibody programs.

### EARLY R&D

In June 2010, Bayer Schering Pharma and OncoMed Pharmaceuticals were collaborating on the discovery, development and commercialization of cancer stem cell-based, Wnt signaling pathway-targeting, anticancer antibody, peptide, and small molecule therapeutics; the research would potentially include five compounds, including OncoMed's lead candidate OMP-18R5. Bayer also took on an additional project to discover and develop further anti-Wnt signalling small molecule therapeutics.

### FINANCIAL

In May 2012, OncoMed planned to raise \$115 million from an IPO of its shares. The company would be listed on the NASDAQ under the ticker symbol 'OMED'. In July 2013, OncoMed reported its IPO would consist of 4.8 million shares priced at \$17.00 per share. Underwriters would be granted a 30-day option to buy 720,000 additional shares. Later that month, the initial public offering of 5,520,000 shares was completed and the underwriters exercised their option to purchase up to 720,000 additional shares of common stock; by that time, the company raised gross proceeds of \$94 million from the IPO. In December 2013, NASDAQ reported that, OncoMed would be added to the NASDAQ

[Return to Table of Contents](#)



Biotechnology Index under the ticker symbol 'OMED', as a result of the annual re-ranking, which would become effective prior to market open on December 23, 2013.

In November 2008, OncoMed completed the final \$93 million tranche of its series B financing round. A total of \$154 million was raised from the financing.


In September 2005, OncoMed raised \$13.9 million in a series A preferred stock financing.

## PRODUCT PORTFOLIO SUMMARY

### DRUGS

#### Drugs by Indication

Active Drugs by Indication Chart




[Return to Table of Contents](#)

## Drugs by Indication Table

Indication	Active	Inactive	Total
Neoplasm	8	0	8
Gastrointestinal disease	2	0	2
Respiratory disease	2	0	2
Genitourinary disease	1	0	1
Hematological disease	1	0	1
Endocrine disease	1	0	1
Gynecology and obstetrics	1	0	1

## Drugs by Highest Status

### Active Drugs by Highest Status Chart



## Drugs by Highest Status Table

Development Status	Number of Drugs
Phase 2 Clinical	2
Phase 1 Clinical	3
Discovery	3

[Return to Table of Contents](#)

## DEALS

Deal Type	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Technology - Other Proprietary	0	0	2	0	2
Drug - Funding	1	0	0	0	1
Drug - Early Research/Development	0	0	1	0	1
Drug - Development/Commercialization License	3	0	0	0	3
Drug - Manufacturing/Supply	0	0	1	0	1
Drug - Development Services	0	0	2	0	2
Technology - Delivery/Formulation	0	0	1	0	1
Technology - Target Validation	0	0	1	0	1

## CLINICAL TRIALS

### Trials by Condition Studied

Condition Studied	Ongoing	All
Neoplasm	12	18
Endocrine disease	5	9
Gastrointestinal disease	4	7
Gynecology and obstetrics	2	4
Respiratory disease	3	3
Genitourinary disease	1	3
Immune disorder	1	1
Hematological disease	1	1

### Trials by Phase

Phase	Ongoing	All
Phase 2	1	1
Phase 1	12	18

### Phase Definitions

#### Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

#### Phase 2 Clinical

[Return to Table of Contents](#)





Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

#### Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

### PATENTS \*

Indication	As Owner	As Third Party	Total
Cardiovascular disease	2	0	2
Endocrine disease	20	0	20
Gastrointestinal disease	20	0	20
Genitourinary disease	16	0	16
Hematological disease	2	0	2
Andrology	10	0	10
Immune disorder	2	1	3
Musculoskeletal disease	0	1	1
Neoplasm	35	0	35
Neurological disease	1	1	2
Respiratory disease	15	0	15
Inflammatory disease	0	1	1
Gynecology and obstetrics	20	0	20
Dermatological disease	7	0	7

\* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

[Return to Table of Contents](#)

## PRODUCT PORTFOLIO DRUG PIPELINE DETAIL

**PLEASE NOTE:** Highest status refers to highest development of that drug for one of the active companies

### demcizumab

#### demcizumab SNAPSHOT

<b>Drug Name</b>	demcizumab
<b>Key Synonyms</b>	demcizumab
<b>Originator Company</b>	OncoMed Pharmaceuticals Inc
<b>Active Companies</b>	OncoMed Pharmaceuticals Inc;Celgene Corp
<b>Inactive Companies</b>	
<b>Highest Status</b>	Phase 2 Clinical
<b>Active Indications</b>	Non-small-cell lung cancer;Pancreas tumor;Solid tumor;Ovary tumor;Colorectal tumor;Cancer
<b>Target-based Actions</b>	Delta-like protein ligand 4 inhibitor;Notch receptor modulator
<b>Other Actions</b>	Anticancer monoclonal antibody;Angiogenesis inhibitor
<b>Technologies</b>	Biological therapeutic;Intravenous formulation;Infusion;Monoclonal antibody humanized;Immunoglobulin-G
<b>Last Change Date</b>	30-Jan-2014

#### demcizumab DEVELOPMENT PROFILE

##### SUMMARY

OncoMed Pharmaceuticals (OMP), in collaboration with Celgene, is developing demcizumab (OMP-21M18), the lead in a series of humanized anti-DLL4 (delta-like ligand 4) IgG2 mAbs targeting tumor stem cells and inhibiting angiogenesis for the potential iv treatment of cancers, including ovarian cancer,.. In September 2013, a phase Ib/II trial was initiated in patients with platinum-resistant ovarian cancer, fallopian tube cancer or primary peritoneal cancer. In August 2008, a phase I trial in solid tumors began; in April 2011, the trial was ongoing . In October 2010, phase Ib trials in Australia and New Zealand were initiated ; in December 2011, the phase Ib trials for pancreatic cancer and NSCLC in Spain, New Zealand and Australia, and colorectal cancer in Australia and New Zealand were ongoing, ; in October 2013, results were presented for NSCLC; in January 2014, data from the ongoing pancreatic cancer trial were presented . In January 2014, data from phase Ib trials were expected in 2014. In January 2013, the FDA lifted the previously placed partial clinical hold. By February 2011, phase II trials in pancreatic and breast cancer were being planned. In October 2013, the company was planning to initiate a phase II trial of demcizumab with carboplatin and pemetrexed in first-line NSCLC in 2014. In January 2014, OncoMed was planning to initiate a phase II trial in combination with gemcitabine and nab-paclitaxel in patients with first-line pancreatic cancer in the second half of 2014. In March 2012, the company was seeking to outlicense the antibody.

#### demcizumab DEVELOPMENT STATUS

##### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
---------	------------	---------	--------------------	------

[Return to Table of Contents](#)



Company	Indication	Country	Development Status	Date
OncoMed Pharmaceuticals Inc	Ovary tumor	US	Phase 2 Clinical	19-Sep-2013
Celgene Corp	Cancer	US	Phase 1 Clinical	03-Dec-2013
OncoMed Pharmaceuticals Inc	Colorectal tumor	Australia	Phase 1 Clinical	28-Oct-2010
OncoMed Pharmaceuticals Inc	Colorectal tumor	New Zealand	Phase 1 Clinical	28-Oct-2010
OncoMed Pharmaceuticals Inc	Non-small-cell lung cancer	Australia	Phase 1 Clinical	28-Oct-2010
OncoMed Pharmaceuticals Inc	Non-small-cell lung cancer	New Zealand	Phase 1 Clinical	28-Oct-2010
OncoMed Pharmaceuticals Inc	Non-small-cell lung cancer	Spain	Phase 1 Clinical	28-Oct-2010
OncoMed Pharmaceuticals Inc	Pancreas tumor	Australia	Phase 1 Clinical	28-Oct-2010
OncoMed Pharmaceuticals Inc	Pancreas tumor	New Zealand	Phase 1 Clinical	28-Oct-2010
OncoMed Pharmaceuticals Inc	Pancreas tumor	Spain	Phase 1 Clinical	28-Oct-2010
OncoMed Pharmaceuticals Inc	Solid tumor	US	Phase 1 Clinical	29-Aug-2009
OncoMed Pharmaceuticals Inc	Cancer	US	Discovery	21-Feb-2007

## demcizumab DRUG NAMES

Names	Type
OMP-90R210	Research Code
tumor stem cell-targeting humanized monoclonal antibodies (cancer), OncoMed	
anti-DLL4 humanized monoclonal antibodies (cancer), OncoMed	
tumor stem cell-targeting humanized mAbs (cancer), OncoMed	
demcizumab	INN, USAN
OMP-21M18	Research Code

## demcizumab CLINICAL TRIALS

### Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Ovary tumor											
0	0	0	0	0	0	1	3	0	0	1	3

[Return to Table of Contents](#)

Fallopian tube cancer											
0	0	0	0	0	0	1	1	0	0	1	1
Peritoneal tumor											
0	0	0	0	0	0	1	1	0	0	1	1
Metastatic non small cell lung cancer											
0	0	0	0	0	0	1	1	0	0	1	1
Colorectal tumor											
0	0	0	0	0	0	0	1	0	0	0	1
Solid tumor											
0	0	0	0	0	0	0	1	0	0	0	1
Metastatic pancreas cancer											
0	0	0	0	0	0	0	1	0	0	0	1

### Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	0	0	0	2	7	0	0	2	7

### Phase Definitions

#### Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

#### Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

#### Phase 1 Clinical


Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

[Return to Table of Contents](#)

demcizumab DEALS AND PATENTS

DEALS

Deals by Parent Company Chart




Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
OncoMed Pharmaceuticals Inc	2	0	3	0	5
Novotech (Australia) Pty Ltd	1	0	0	0	1
GlaxoSmithKline plc	0	0	1	0	1
SynCo BioPartners	1	0	0	0	1
Celgene Corp	0	0	1	0	1
University of Texas System	1	0	0	0	1

[Return to Table of Contents](#)

Deals by Type Chart




Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Development Services	2	0	2
Drug - Development/Commercialization License	2	0	2
Drug - Manufacturing/Supply	1	0	1

[Return to Table of Contents](#)

PATENTS

Patents by Parent Company Chart




Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
OncoMed Pharmaceuticals Inc	7	0	7
University of Michigan	0	1	1
Individual	1	0	1

[Return to Table of Contents](#)

Patents by Drug Relationship Type Chart



Patents by Drug Relationship Type Table

Drug Relationship	Total
Component of Combination	3
New use	2
General interest	2
Product	1
Formulation	1



## OMP-59R5

### OMP-59R5 SNAPSHOT

<b>Drug Name</b>	OMP-59R5
<b>Key Synonyms</b>	tarextumab
<b>Originator Company</b>	OncoMed Pharmaceuticals Inc
<b>Active Companies</b>	OncoMed Pharmaceuticals Inc;GlaxoSmithKline plc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Phase 2 Clinical
<b>Active Indications</b>	Pancreas tumor;Small-cell lung cancer;Solid tumor
<b>Target-based Actions</b>	Notch-2 receptor antagonist;Notch-3 receptor antagonist
<b>Other Actions</b>	Anticancer;Anticancer monoclonal antibody
<b>Technologies</b>	Biological therapeutic;Parenteral formulation unspecified;Monoclonal antibody human
<b>Last Change Date</b>	23-Jan-2014

### OMP-59R5 DEVELOPMENT PROFILE

#### SUMMARY

Oncomed in collaboration with GlaxoSmithKline, is developing OMP-59R5 presumed to be tarextumab, a fully human monoclonal antibody that binds to the conserved epitope of notch 2 and 3 receptors, for the potential treatment of advanced solid tumors, including pancreatic cancer and small cell lung carcinoma. In October 2012, a phase Ib/II trial was initiated in pancreatic cancer; in January 2014, phase Ib data were presented. In May 2013, the phase I portion of a phase Ib/II trial in patients with first-line extensive-stage small cell lung carcinoma (SCLC) was initiated. In January 2011, dosing began in a phase I trial in solid tumors; data were presented in November 2012.

### OMP-59R5 DEVELOPMENT STATUS

#### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
GlaxoSmithKline plc	Pancreas tumor	US	Phase 2 Clinical	04-Oct-2012
OncoMed Pharmaceuticals Inc	Pancreas tumor	US	Phase 2 Clinical	04-Oct-2012
GlaxoSmithKline plc	Small-cell lung cancer	US	Phase 1 Clinical	14-May-2013
GlaxoSmithKline plc	Solid tumor	US	Phase 1 Clinical	11-Jan-2011
OncoMed Pharmaceuticals Inc	Small-cell lung cancer	US	Phase 1 Clinical	14-May-2013
OncoMed Pharmaceuticals Inc	Solid tumor	US	Phase 1 Clinical	11-Jan-2011

[Return to Table of Contents](#)

## OMP-59R5 DRUG NAMES

Names	Type
tarextumab	PINN
OMP-59R5	Research Code
notch 2/3 receptor inhibitor (mAb, solid tumors), Oncomed pharmaceuticals	
notch receptor modulator (mAb, solid tumor), Oncomed/GlaxoSmithKline	

## OMP-59R5 CLINICAL TRIALS

### Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Small-cell lung cancer											
0	0	0	0	0	0	1	1	0	0	1	1
Metastatic pancreas cancer											
0	0	0	0	1	1	0	0	0	0	1	1
Advanced solid tumor											
0	0	0	0	0	0	1	1	0	0	1	1

### Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	0	1	1	2	2	0	0	3	3

### Phase Definitions

#### Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

#### Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

#### Phase 1 Clinical


Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

[Return to Table of Contents](#)

OMP-59R5 DEALS AND PATENTS

DEALS

Deals by Parent Company Chart




Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
OncoMed Pharmaceuticals Inc	1	0	1	0	2
GlaxoSmithKline plc	0	0	1	0	1
MorphoSys AG	1	0	0	0	1

[Return to Table of Contents](#)

Deals by Type Chart




Deals by Type Table

Deal Type	Active	Inactive	Total
Technology - Delivery/Formulation	1	0	1
Drug - Development/Commercialization License	1	0	1

[Return to Table of Contents](#)

PATENTS


Patents by Parent Company Chart



Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
OncoMed Pharmaceuticals Inc	2	0	2

Patents by Drug Relationship Type Chart



[Return to Table of Contents](#)

Patents by Drug Relationship Type Table

Drug Relationship	Total
Formulation	1
General interest	1

[Return to Table of Contents](#)

## OMP-52M51

### OMP-52M51 SNAPSHOT

<b>Drug Name</b>	OMP-52M51
<b>Key Synonyms</b>	
<b>Originator Company</b>	OncoMed Pharmaceuticals Inc
<b>Active Companies</b>	GlaxoSmithKline plc;OncoMed Pharmaceuticals Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Phase 1 Clinical
<b>Active Indications</b>	Hematological neoplasm;Cancer;Solid tumor
<b>Target-based Actions</b>	Notch-1 receptor antagonist
<b>Other Actions</b>	Anticancer monoclonal antibody
<b>Technologies</b>	Biological therapeutic;Parenteral formulation unspecified;Monoclonal antibody humanized
<b>Last Change Date</b>	15-Nov-2013

### OMP-52M51 DEVELOPMENT PROFILE

#### SUMMARY

Oncomed, in collaboration with GlaxoSmithKline, is developing OMP-52M51, a cancer stem cell based humanized mAb that targets notch 1 receptor, for the potential treatment for cancer, including, solid tumors and hematological cancers,. In December 2012, a phase Ia trial for hematological cancers was initiated ; in October 2013, data were presented . In March 2013, a phase I trial for solid tumors was initiated.

### OMP-52M51 DEVELOPMENT STATUS

#### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
GlaxoSmithKline plc	Cancer	US	Phase 1 Clinical	09-Nov-2012
GlaxoSmithKline plc	Hematological neoplasm	US	Phase 1 Clinical	21-Dec-2012
GlaxoSmithKline plc	Solid tumor	US	Phase 1 Clinical	07-Mar-2013
OncoMed Pharmaceuticals Inc	Cancer	UK	Phase 1 Clinical	09-Nov-2012
OncoMed Pharmaceuticals Inc	Hematological neoplasm	US	Phase 1 Clinical	21-Dec-2012
OncoMed Pharmaceuticals Inc	Solid tumor	US	Phase 1 Clinical	07-Mar-2013

[Return to Table of Contents](#)



## OMP-52M51 DRUG NAMES

Names	Type
anti-notch 1 mAb (cancer), Oncomed	
notch 1 receptor inhibitor (mAb, cancer), Oncomed	
OMP-52M51	Research Code

## OMP-52M51 CLINICAL TRIALS

### Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Advanced solid tumor											
0	0	0	0	0	0	1	1	0	0	1	1
Lymphoma											
0	0	0	0	0	0	1	1	0	0	1	1

### Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	0	0	0	2	2	0	0	2	2

### Phase Definitions

#### Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

#### Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

#### Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0


[Return to Table of Contents](#)



OMP-52M51 DEALS AND PATENTS

DEALS

Deals by Parent Company Chart



Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
OncoMed Pharmaceuticals Inc	1	0	0	0	1
GlaxoSmithKline plc	0	0	1	0	1

[Return to Table of Contents](#)

Deals by Type Chart




Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Development/Commercialization License	1	0	1

[Return to Table of Contents](#)

PATENTS


Patents by Parent Company Chart



Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
OncoMed Pharmaceuticals Inc	2	0	2

Patents by Drug Relationship Type Chart



[Return to Table of Contents](#)

Patents by Drug Relationship Type Table

Drug Relationship	Total
New use	1
Product	1

[Return to Table of Contents](#)

## vantictumab

### vantictumab SNAPSHOT

<b>Drug Name</b>	vantictumab
<b>Key Synonyms</b>	vantictumab
<b>Originator Company</b>	OncoMed Pharmaceuticals Inc
<b>Active Companies</b>	OncoMed Pharmaceuticals Inc;Bayer Schering Pharma AG
<b>Inactive Companies</b>	
<b>Highest Status</b>	Phase 1 Clinical
<b>Active Indications</b>	Cancer
<b>Target-based Actions</b>	Frizzled-7 receptor antagonist
<b>Other Actions</b>	Anticancer monoclonal antibody;Stem cell inhibitor
<b>Technologies</b>	Biological therapeutic;Intravenous formulation;Infusion;Monoclonal antibody human;Immunoglobulin-G
<b>Last Change Date</b>	05-Dec-2013

### vantictumab DEVELOPMENT PROFILE

#### SUMMARY

OncoMed Pharmaceuticals, in collaboration with Bayer Schering Pharma, is developing vantictumab (OMP-18R5), a fully human IgG2 mAb and the lead in a series of mAb Wnt pathway inhibitors that targets frizzled-7 receptor, as a cancer stem cell inhibitor for the potential iv infusion treatment of cancer „. In May 2011, a phase I trial was initiated. In May 2012, OncoMed planned to advance the drug into phase II trials. By August 2012, phase I data were available. In June 2013, phase I data were presented,.

### vantictumab DEVELOPMENT STATUS

#### CURRENT DEVELOPMENT STATUS

<b>Company</b>	<b>Indication</b>	<b>Country</b>	<b>Development Status</b>	<b>Date</b>
Bayer Schering Pharma AG	Cancer	Germany	Phase 1 Clinical	31-Dec-2011
OncoMed Pharmaceuticals Inc	Cancer	US	Phase 1 Clinical	19-May-2011

[Return to Table of Contents](#)



## vantictumab DRUG NAMES

Names	Type
OMP-18R5	Research Code
frizzled-7 receptor targeted mAb (cancer), Oncomed/Bayer Schering	
vantictumab	PINN, USAN
Wnt inhibitors (mAb, cancer), OncoMed Pharmaceuticals	

## vantictumab CLINICAL TRIALS

### Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Metastatic pancreas cancer											
0	0	0	0	0	0	1	2	0	0	1	2
Advanced solid tumor											
0	0	0	0	0	0	1	1	0	0	1	1
Non-small-cell lung cancer											
0	0	0	0	0	0	1	1	0	0	1	1
Metastatic breast cancer											
0	0	0	0	0	0	1	1	0	0	1	1

### Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	0	0	0	4	5	0	0	4	5

### Phase Definitions

#### Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

#### Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

[Return to Table of Contents](#)




## Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0


## vantictumab DEALS AND PATENTS

### DEALS

#### Deals by Parent Company Chart



Active Deals  
Total: 2



#### Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
OncoMed Pharmaceuticals Inc	1	0	1	0	2
MorphoSys AG	1	0	0	0	1
Bayer AG	0	0	1	0	1

[Return to Table of Contents](#)

Deals by Type Chart




Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Development/Commercialization License	1	0	1
Technology - Delivery/Formulation	1	0	1



PATENTS

Patents by Parent Company Chart




Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
OncoMed Pharmaceuticals Inc	5	0	5
Individual	2	0	2

[Return to Table of Contents](#)

Patents by Drug Relationship Type Chart



Patents by Drug Relationship Type Table

Drug Relationship	Total
General interest	2
Component of Combination	1
Product	1
New use	1

## OMP-54F28

### OMP-54F28 SNAPSHOT

Drug Name	OMP-54F28
Key Synonyms	ipafricept
Originator Company	OncoMed Pharmaceuticals Inc
Active Companies	Bayer Schering Pharma AG;OncoMed Pharmaceuticals Inc
Inactive Companies	
Highest Status	Phase 1 Clinical
Active Indications	Solid tumor;Cancer
Target-based Actions	Frizzled-8 receptor antagonist
Other Actions	Stem cell inhibitor;Anticancer
Technologies	Biological therapeutic;Intravenous formulation;Infusion;Protein fusion
Last Change Date	14-Jan-2014

### OMP-54F28 DEVELOPMENT PROFILE

#### SUMMARY

Oncomed, in collaboration with Bayer Schering Pharma is developing OMP-54F28, a fusion protein stem cell inhibitor presumed to be ipafricept, a biological Wnt pathway inhibitor that binds to Frizzled 8 receptor Fc (Fzd8Fc) of a human IgG1 antibody, for the potential iv infusion treatment of cancer,.. In June 2012, a phase I trial was initiated in solid tumors. The first of three planned phase Ib trials of OMP-54F28 began in January 2014.

### OMP-54F28 DEVELOPMENT STATUS

#### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Bayer Schering Pharma AG	Solid tumor	US	Phase 1 Clinical	19-Jun-2012
OncoMed Pharmaceuticals Inc	Solid tumor	US	Phase 1 Clinical	19-Jun-2012
Bayer Schering Pharma AG	Cancer	Germany	Discovery	17-Jun-2010
OncoMed Pharmaceuticals Inc	Cancer	US	Discovery	17-Jun-2010

[Return to Table of Contents](#)



## OMP-54F28 DRUG NAMES

Names	Type
frizzled-8 receptor Fc targeted biologic (cancer), Oncomed/Bayer Schering	
ipafricept	PINN
Wnt pathway targeted biologic (cancer), Oncomed/Bayer Schering	
OMP-54F28	Research Code

## OMP-54F28 CLINICAL TRIALS

### Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Metastatic pancreas cancer											
0	0	0	0	0	0	1	1	0	0	1	1

### Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	0	0	0	2	2	0	0	2	2

### Phase Definitions

#### Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

#### Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

#### Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0


[Return to Table of Contents](#)



OMP-54F28 DEALS AND PATENTS

DEALS

Deals by Parent Company Chart




Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
OncoMed Pharmaceuticals Inc	1	0	0	0	1
Bayer AG	0	0	1	0	1

[Return to Table of Contents](#)

Deals by Type Chart




Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Development/Commercialization License	1	0	1

[Return to Table of Contents](#)

PATENTS


Patents by Parent Company Chart



Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
OncoMed Pharmaceuticals Inc	2	0	2

Patents by Drug Relationship Type Chart



[Return to Table of Contents](#)

Patents by Drug Relationship Type Table

Drug Relationship	Total
Component of Combination	1
Product	1

[Return to Table of Contents](#)



## anti-DLL4/VEGF bispecific mAb (cancer), Oncomed/Celgene

### anti-DLL4/VEGF bispecific mAb (cancer), Oncomed/Celgene SNAPSHOT

<b>Drug Name</b>	anti-DLL4/VEGF bispecific mAb (cancer), Oncomed/Celgene
<b>Key Synonyms</b>	
<b>Originator Company</b>	OncoMed Pharmaceuticals Inc
<b>Active Companies</b>	Celgene Corp;OncoMed Pharmaceuticals Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Discovery
<b>Active Indications</b>	Cancer
<b>Target-based Actions</b>	Delta-like protein ligand 4 inhibitor;VEGF receptor antagonist
<b>Other Actions</b>	Anticancer protein kinase inhibitor;Anticancer monoclonal antibody
<b>Technologies</b>	Monoclonal antibody;Biological therapeutic;Parenteral formulation unspecified
<b>Last Change Date</b>	07-Jan-2014

### anti-DLL4/VEGF bispecific mAb (cancer), Oncomed/Celgene DEVELOPMENT PROFILE

#### SUMMARY

Oncomed, in collaboration with Celgene, is investigating bispecific mAb that inhibits delta-like ligand 4 (DLL4) and VEGF receptor, for the potential treatment of cancers, including colon cancer,. In March 2012, the program was in preclinical development. In April 2013, preclinical data were presented. In March 2012, Oncomed expected to file an IND in 2013.

### anti-DLL4/VEGF bispecific mAb (cancer), Oncomed/Celgene DEVELOPMENT STATUS

#### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Celgene Corp	Cancer	US	Discovery	03-Dec-2013
OncoMed Pharmaceuticals Inc	Cancer	US	Discovery	06-Mar-2012


### anti-DLL4/VEGF bispecific mAb (cancer), Oncomed/Celgene DRUG NAMES

Names	Type
anti-DLL4/VEGF bispecific mAb (cancer), Oncomed	
anti-DLL4/VEGF bispecific mAb (cancer), Oncomed/Celgene	
delta-like protein ligand 4/VEGF inhibitor (mAb, cancer), Oncomed	

[Return to Table of Contents](#)

DEALS

Deals by Parent Company Chart




Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
OncoMed Pharmaceuticals Inc	1	0	0	0	1
Celgene Corp	0	0	1	0	1

[Return to Table of Contents](#)

Deals by Type Chart




Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Development/Commercialization License	1	0	1

[Return to Table of Contents](#)

PATENTS


Patents by Parent Company Chart



Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
OncoMed Pharmaceuticals Inc	2	0	2

Patents by Drug Relationship Type Chart



[Return to Table of Contents](#)

### Patents by Drug Relationship Type Table

Drug Relationship	Total
Product	1
New use	1

[Return to Table of Contents](#)

## RSPO3-LGR pathway inhibitor (antibody, cancer), Oncomed

### RSPO3-LGR pathway inhibitor (antibody, cancer), Oncomed SNAPSHOT

<b>Drug Name</b>	RSPO3-LGR pathway inhibitor (antibody, cancer), Oncomed
<b>Key Synonyms</b>	
<b>Originator Company</b>	OncoMed Pharmaceuticals Inc
<b>Active Companies</b>	OncoMed Pharmaceuticals Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Discovery
<b>Active Indications</b>	Cancer
<b>Target-based Actions</b>	RSPO3 gene inhibitor;Leucine rich repeat containing protein modulator
<b>Other Actions</b>	Anticancer antibody;Anticancer protein kinase inhibitor
<b>Technologies</b>	Antibody;Parenteral formulation unspecified
<b>Last Change Date</b>	04-Feb-2014

### RSPO3-LGR pathway inhibitor (antibody, cancer), Oncomed DEVELOPMENT PROFILE

#### SUMMARY

Oncomed is investigating an antibody that inhibits R Spondin 3 (RSPO3)-leucine-rich repeat containing GPCR (LGR) pathway, for the potential treatment of cancer,. In March 2012, the program was in preclinical development and at that time, the company planned to file an IND in 2013. In July 2013, the company planned to file an IND 'as early as 2014'. In February 2014, an IND was planned for late 2014 or early 2015.

### RSPO3-LGR pathway inhibitor (antibody, cancer), Oncomed DEVELOPMENT STATUS

#### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
OncoMed Pharmaceuticals Inc	Cancer	US	Discovery	06-Mar-2012


### RSPO3-LGR pathway inhibitor (antibody, cancer), Oncomed DRUG NAMES

Names	Type
RSPO-LGR pathway modulator (antibody, cancer), Oncomed	
RSPO-LGR pathway modulators (cancer), Oncomed	
RSPO3-LGR pathway inhibitor (antibody, cancer), Oncomed	
R Spondin-leucine-rich protein containing GPCR pathway modulators (cancer), Oncomed	

[Return to Table of Contents](#)

DEALS

Deals by Parent Company Chart




Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Celgene Corp	0	0	1	0	1
OncoMed Pharmaceuticals Inc	1	0	0	0	1

[Return to Table of Contents](#)

Deals by Type Chart



Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Development/Commercialization License	1	0	1

[Return to Table of Contents](#)



## Wnt signalling pathway targeted small molecules (cancer), Oncomed/Bayer Schering Pharma

### Wnt signalling pathway targeted small molecules (cancer), Oncomed/Bayer Schering Pharma SNAPSHOT

<b>Drug Name</b>	Wnt signalling pathway targeted small molecules (cancer), Oncomed/Bayer Schering Pharma
<b>Key Synonyms</b>	
<b>Originator Company</b>	OncoMed Pharmaceuticals Inc
<b>Active Companies</b>	Bayer Schering Pharma AG;OncoMed Pharmaceuticals Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Discovery
<b>Active Indications</b>	Cancer
<b>Target-based Actions</b>	
<b>Other Actions</b>	Anticancer
<b>Technologies</b>	Small molecule therapeutic
<b>Last Change Date</b>	09-Mar-2012

### Wnt signalling pathway targeted small molecules (cancer), Oncomed/Bayer Schering Pharma DEVELOPMENT PROFILE

#### SUMMARY

Oncomed, in collaboration with Bayer Schering Pharma is investigating small molecules that targets Wnt signalling pathway, for the potential treatment of cancer. In March 2012, the program was in preclinical development .

### Wnt signalling pathway targeted small molecules (cancer), Oncomed/Bayer Schering Pharma DEVELOPMENT STATUS

#### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Bayer Schering Pharma AG	Cancer	Germany	Discovery	14-Jun-2010
OncoMed Pharmaceuticals Inc	Cancer	US	Discovery	14-Jun-2010

### Wnt signalling pathway targeted small molecules (cancer), Oncomed/Bayer Schering Pharma DRUG NAMES


Names	Type
Wnt signalling pathway targeted small molecules (cancer), Oncomed/Bayer Schering Pharma	

[Return to Table of Contents](#)

Wnt signalling pathway targeted small molecules (cancer), Oncomed/Bayer Schering Pharma DEALS AND PATENTS

DEALS

Deals by Parent Company Chart




Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Bayer AG	0	0	1	0	1
OncoMed Pharmaceuticals Inc	1	0	0	0	1

[Return to Table of Contents](#)

Deals by Type Chart



Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Development/Commercialization License	1	0	1

[Return to Table of Contents](#)

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

[http://cortellis.thomsonreuters.com/cortellis\\_for\\_you/?cid=thomsonone](http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone).

For subscription information, e-mail [scientific.lifesciences@thomsonreuters.com](mailto:scientific.lifesciences@thomsonreuters.com).

© 2012 Thomson Reuters. All rights reserved.  
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)

